March 4, 2022 -- Fortis Life Sciences has acquired Abcore, extending Fortis’ capabilities into the antibody discovery market serving biopharma customers developing antibody and nanobody-based therapeutics.
Abcore provides antibody and nanobody products and services. Abcore has built an entire platform for nanobody and single domain (VHH) antibody discovery, based on proprietary phage display libraries.
Fortis Life Sciences is a strategic platform company providing capital, expertise, and operational resources to enable the growth and success of founder-led life sciences tools companies.
Financial details of the acquisition were not disclosed.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
